Provided by Tiger Trade Technology Pte. Ltd.

ASCLETIS-B

9.450
-0.600-5.97%
Volume:3.98M
Turnover:38.67M
Market Cap:9.94B
PE:-21.84
High:10.130
Open:9.585
Low:9.450
Close:10.050
52wk High:19.860
52wk Low:7.950
Shares:1.05B
HK Float Shares:1.05B
Volume Ratio:1.08
T/O Rate:0.38%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.433
ROE:-28.59%
ROA:-19.64%
PB:3.75
PE(LYR):-21.84
PS:8980.99

Loading ...

ASCLETIS-B Executes Share Buyback, Spending HK$1.86 Million

Stock News
·
Jun 16

Ascletis Pharma files HKEX next-day disclosure return reporting share repurchase for cancellation

Reuters
·
Jun 16

ASCLETIS-B Executes Share Buyback, Spending HK$1,918,300 on June 15

Stock News
·
Jun 15

Ascletis Pharma files HKEX next-day return disclosing share repurchase for cancellation

Reuters
·
Jun 15

One Ascletis Pharma Insider Has Reduced Their Stake

Simply Wall St.
·
Jun 13

Ascletis Pharma launches fresh HKD 1.97 million buyback; cumulative repurchases reach 7.89 million shares

Bulletin Express
·
Jun 11

ASCLETIS-B Executes HK$1.97 Million Share Buyback on June 11

Stock News
·
Jun 11

Ascletis Pharma Executes HKD 2.00 Million Share Buyback; Cumulative Repurchases Reach 7.69 Million Shares

Bulletin Express
·
Jun 10

ASCLETIS-B Executes Share Buyback, Spending Nearly HK$2 Million

Stock News
·
Jun 10

Ascletis Pharma Carries Out HKD 2.01 Million Share Buyback; Cumulative Repurchases Climb to 7.49 Million Shares

Bulletin Express
·
Jun 09

Ascletis Pharma repurchases 200,000 shares at HK$9.88–10.26; cumulative buy-backs under mandate rise to 7.29 million

Bulletin Express
·
Jun 08

ASCLETIS-B Executes Share Buyback, Spending HK$2 Million on June 8

Stock News
·
Jun 08

ASCLETIS-B Presents Compelling Clinical and Preclinical Data for Obesity Portfolio at ADA 2026, Reinforcing Pipeline Differentiation

Stock News
·
Jun 08

Ascletis Highlights Robust Obesity Pipeline with Positive ASC30, ASC37 and ASC39 Results at ADA 2026

Bulletin Express
·
Jun 08

Ascletis | Key Resolutions and Timetable for the 2026 Annual General Meeting

Bulletin Express
·
Jun 05

Ascletis Pharma to Hold 2026 AGM; Seeks 20% Share Issuance Mandate, 10% Buy-Back Authority and Director Re-elections

Bulletin Express
·
Jun 05

HK Movers | Biotech Stocks Jump. Asymchem up Nearly 7%; SKB Bio up About 6%; Hengrui Pharma, Pharmaron, InnoGen up over 4%; Wuxi Apptec up 3%; Laekna, Joinn, Remegen up over 2%

Tiger Newspress
·
Jun 05

ASCLETIS-B Executes Share Buyback Valued at Approximately HK$2.03 Million

Stock News
·
Jun 04

Ascletis Pharma files HKEX next-day disclosure return, reports share buyback at HKD 10.31-9.8 each

Reuters
·
Jun 04

Ascletis Pharma spends HK$2.01 million on latest buyback; cumulative repurchases reach 6.69 million shares

Bulletin Express
·
Jun 03